VivoSim Labs Inc. (VIVS) had a rough Thursday, with shares plunging more than 25% after the company announced a private placement that has investors worried about dilution. The biotech firm is selling about 4.71 million shares (or equivalent securities) along with warrants to a healthcare-focused institutional investor, all at a combined effective price of $0.85 per share. That's a steep discount to where the stock was trading before the news.

The deal brings in roughly $4 million in gross proceeds before fees. The warrants, which can be exercised at $0.85 per share once shareholders give the green light, will be good for five years. But that's not the only warrant action: VivoSim also plans to amend some older warrants from May 2024 covering 520,833 shares, dropping the exercise price from $9.60 to $0.85 and extending their term to five years from the approval date. That's a big swing, and it means more potential dilution if those warrants get exercised.

The offering is expected to close around July 17, 2026, and the company says the cash will go toward working capital and general corporate purposes. Translation: they need the money to keep the lights on and fund their research.

So what does VivoSim actually do? Formerly known as Organovo Holdings, the company is focused on developing FXR314, a treatment for inflammatory bowel disease (IBD), including ulcerative colitis. They also use 3D human tissues to study liver and intestinal toxicity, which is becoming more important as regulators push to reduce animal testing. It's a niche but potentially valuable area.

The stock was down about 29% at $0.61 at the time of publication, according to market data. For a company that's still in the development stage, raising capital is essential, but the way you do it matters. A dilutive offering like this one can spook investors, and Thursday's price action shows they're not happy. VivoSim's ability to balance funding needs with shareholder sentiment will be key going forward.